PeptidePedia The community reference

List of GLP-1 receptor agonists (revision 12)

Old revision·08:27, 26 Jan 2025·Retention_Time_Rae

This is an old revision of this page, as it stood at 08:27, 26 Jan 2025, saved by Retention_Time_Rae with the summary renumber the timeline after inserting the 2023 entry. It may differ substantially from the current revision, and any error it contains may since have been corrected.
List of GLP-1 receptor agonistsReference material
ScopeAgonists at the GLP-1 receptor, alone or with others
ExcludedDPP-4 inhibitors, which raise endogenous hormone
List infobox · conventions

This list enumerates agonists at the GLP-1 receptor, including those that also engage other receptors of the glucagon-secretin family. DPP-4 inhibitors are excluded: they raise endogenous incretin concentrations rather than agonising the receptor directly. See Dipeptidyl peptidase-4.[1]

Status is given as approved or investigational without specifying jurisdiction, since approval differs between countries. See Regulatory status by jurisdiction.[2]

Compounds appearing here are covered by their own articles where one exists. Inclusion is not an endorsement, and several entries are investigational compounds not approved anywhere.[3]

GLP-1 receptor agonists

[edit]
CompoundRouteIntervalStatus
ExenatideSubcutaneousTwice daily or weeklyApproved
LixisenatideSubcutaneousDailyApproved
LiraglutideSubcutaneousDailyApproved
DulaglutideSubcutaneousWeeklyApproved
SemaglutideSubcutaneousWeeklyApproved
Oral semaglutideOralDailyApproved
OrforglipronOralDailyInvestigational

The list spans three architectures: exendin-derived peptides, acylated GLP-1 analogues, an Fc fusion, and a non-peptide small molecule. See GLP-1 receptor agonist for how each solves the half-life problem.[1]

Multi-receptor agonists

[edit]
CompoundReceptorsStatus
TirzepatideGIP, GLP-1Approved
SurvodutideGlucagon, GLP-1Investigational
EfinopegdutideGlucagon, GLP-1Investigational
MazdutideGlucagon, GLP-1Investigational
RetatrutideGIP, GLP-1, glucagonInvestigational

These are treated at Dual incretin agonist and Triple agonist. Their receptor ratios are fixed by chemistry and are not comparable between publications, since reported potencies are assay-dependent.[1]

See also

References

  1. ^ a b c Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
  2. ^ American Diabetes Association. "Standards of Care in Diabetes." Diabetes Care 47(Suppl 1) (2024).
  3. ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.
Categories: